308 related articles for article (PubMed ID: 30790684)
41. The cyclic GMP-AMP synthetase-STING signaling pathway is required for both the innate immune response against HBV and the suppression of HBV assembly.
Dansako H; Ueda Y; Okumura N; Satoh S; Sugiyama M; Mizokami M; Ikeda M; Kato N
FEBS J; 2016 Jan; 283(1):144-56. PubMed ID: 26471009
[TBL] [Abstract][Full Text] [Related]
42. Discovery and Mechanistic Study of a Novel Human-Stimulator-of-Interferon-Genes Agonist.
Zhang X; Liu B; Tang L; Su Q; Hwang N; Sehgal M; Cheng J; Ma J; Zhang X; Tan Y; Zhou Y; Duan Z; DeFilippis VR; Viswanathan U; Kulp J; Du Y; Guo JT; Chang J
ACS Infect Dis; 2019 Jul; 5(7):1139-1149. PubMed ID: 31060350
[TBL] [Abstract][Full Text] [Related]
43. Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy.
Shae D; Becker KW; Christov P; Yun DS; Lytton-Jean AKR; Sevimli S; Ascano M; Kelley M; Johnson DB; Balko JM; Wilson JT
Nat Nanotechnol; 2019 Mar; 14(3):269-278. PubMed ID: 30664751
[TBL] [Abstract][Full Text] [Related]
44. STING-associated lung disease in mice relies on T cells but not type I interferon.
Luksch H; Stinson WA; Platt DJ; Qian W; Kalugotla G; Miner CA; Bennion BG; Gerbaulet A; Rösen-Wolff A; Miner JJ
J Allergy Clin Immunol; 2019 Jul; 144(1):254-266.e8. PubMed ID: 30772497
[TBL] [Abstract][Full Text] [Related]
45. Identification of Novel Carbocyclic Pyrimidine Cyclic Dinucleotide STING Agonists for Antitumor Immunotherapy Using Systemic Intravenous Route.
Vyskocil S; Cardin D; Ciavarri J; Conlon J; Cullis C; England D; Gershman R; Gigstad K; Gipson K; Gould A; Greenspan P; Griffin R; Gulavita N; Harrison S; Hu Z; Hu Y; Hata A; Huang J; Huang SC; Janowick D; Jones M; Kolev V; Langston SP; Lee HM; Li G; Lok D; Ma L; Mai D; Malley J; Matsuda A; Mizutani H; Mizutani M; Molchanova N; Nunes E; Pusalkar S; Renou C; Rowland S; Sato Y; Shaw M; Shen L; Shi Z; Skene R; Soucy F; Stroud S; Xu H; Xu T; Abu-Yousif AO; Zhang J
J Med Chem; 2021 May; 64(10):6902-6923. PubMed ID: 34000802
[TBL] [Abstract][Full Text] [Related]
46. Antitumor Activity of cGAMP via Stimulation of cGAS-cGAMP-STING-IRF3 Mediated Innate Immune Response.
Li T; Cheng H; Yuan H; Xu Q; Shu C; Zhang Y; Xu P; Tan J; Rui Y; Li P; Tan X
Sci Rep; 2016 Jan; 6():19049. PubMed ID: 26754564
[TBL] [Abstract][Full Text] [Related]
47. Agonist of stimulator of interferon genes as antitumor agents: a patent review (2008-2020).
Chen NN; Zhang H; You QD; Xu XL
Expert Opin Ther Pat; 2021 Jun; 31(6):563-584. PubMed ID: 33459063
[TBL] [Abstract][Full Text] [Related]
48. Effects of STING stimulation on macrophages: STING agonists polarize into "classically" or "alternatively" activated macrophages?
Ohkuri T; Kosaka A; Nagato T; Kobayashi H
Hum Vaccin Immunother; 2018 Feb; 14(2):285-287. PubMed ID: 29064738
[TBL] [Abstract][Full Text] [Related]
49. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
[TBL] [Abstract][Full Text] [Related]
50. The cGAS-STING pathway is a therapeutic target in a preclinical model of hepatocellular carcinoma.
Thomsen MK; Skouboe MK; Boularan C; Vernejoul F; Lioux T; Leknes SL; Berthelsen MF; Riedel M; Cai H; Joseph JV; Perouzel E; Tiraby M; Vendelbo MH; Paludan SR
Oncogene; 2020 Feb; 39(8):1652-1664. PubMed ID: 31740782
[TBL] [Abstract][Full Text] [Related]
51. Diminished Innate Antiviral Response to Adenovirus Vectors in cGAS/STING-Deficient Mice Minimally Impacts Adaptive Immunity.
Anghelina D; Lam E; Falck-Pedersen E
J Virol; 2016 Jul; 90(13):5915-27. PubMed ID: 27076643
[TBL] [Abstract][Full Text] [Related]
52. Overcoming resistance to STING agonist therapy to incite durable protective antitumor immunity.
Lemos H; Ou R; McCardle C; Lin Y; Calver J; Minett J; Chadli A; Huang L; Mellor AL
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32847988
[TBL] [Abstract][Full Text] [Related]
53. Design, Synthesis, and Biological Evaluation of Amidobenzimidazole Derivatives as Stimulator of Interferon Genes (STING) Receptor Agonists.
Xi Q; Wang M; Jia W; Yang M; Hu J; Jin J; Chen X; Yin D; Wang X
J Med Chem; 2020 Jan; 63(1):260-282. PubMed ID: 31820985
[TBL] [Abstract][Full Text] [Related]
54. Potential for treatment benefit of STING agonists plus immune checkpoint inhibitors in oral squamous cell carcinoma.
Zhu C; Li J; Yao M; Fang C
BMC Oral Health; 2021 Oct; 21(1):506. PubMed ID: 34625078
[TBL] [Abstract][Full Text] [Related]
55. RRM2 silencing suppresses malignant phenotype and enhances radiosensitivity via activating cGAS/STING signaling pathway in lung adenocarcinoma.
Jiang X; Li Y; Zhang N; Gao Y; Han L; Li S; Li J; Liu X; Gong Y; Xie C
Cell Biosci; 2021 Apr; 11(1):74. PubMed ID: 33858512
[TBL] [Abstract][Full Text] [Related]
56. Detection of Cyclic Dinucleotides by STING.
Du XX; Su XD
Methods Mol Biol; 2017; 1657():59-69. PubMed ID: 28889286
[TBL] [Abstract][Full Text] [Related]
57. STING pathway agonism as a cancer therapeutic.
Flood BA; Higgs EF; Li S; Luke JJ; Gajewski TF
Immunol Rev; 2019 Jul; 290(1):24-38. PubMed ID: 31355488
[TBL] [Abstract][Full Text] [Related]
58. An updated patent review of stimulator of interferon genes agonists (2021 - present).
Xin GF; Chen NN; Li LL; Liu XC; Che CC; Wu BD; You QD; Xu XL
Expert Opin Ther Pat; 2024 May; 34(5):297-313. PubMed ID: 38849323
[TBL] [Abstract][Full Text] [Related]
59. Targeting macrophage priming by polyphyllin VII triggers anti-tumor immunity via STING-governed cytotoxic T-cell infiltration in lung cancer.
Yu J; Deng H; Xu Z
Sci Rep; 2020 Dec; 10(1):21360. PubMed ID: 33288772
[TBL] [Abstract][Full Text] [Related]
60. Combining VPS34 inhibitors with STING agonists enhances type I interferon signaling and anti-tumor efficacy.
Yu Y; Bogdan M; Noman MZ; Parpal S; Bartolini E; Van Moer K; Kleinendorst SC; Bilgrav Saether K; Trésaugues L; Silvander C; Lindström J; Simeon J; Timson MJ; Al-Hashimi H; Smith BD; Flynn DL; Alexeyenko A; Viklund J; Andersson M; Martinsson J; Pokrovskaja Tamm K; De Milito A; Janji B
Mol Oncol; 2024 Mar; ():. PubMed ID: 38506049
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
